Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium [Yahoo! Finance]
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: Yahoo! Finance
Shares of Merus NV soared to a new record high on Monday, as investors gobbled up shares following news that it was set to be acquired by Genmab AS at a 41-percent premium. In a statement, Genmab AS said that it entered into an agreement with Merus NV (NASDAQ:MRUS) for the acquisition of the latter, through its subsidiary, Purchaser, for $8 billion. Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium Pixabay/Public domain Under the deal, Purchaser will acquire all of Merus NV's (NASDAQ:MRUS) outstanding shares at a price of $97 apiece. The tender offer is subject to the satisfaction of customary closing conditions, including a minimum acceptance condition of at least 80 percent of Merus NV's (NASDAQ:MRUS) common shares. The companies said the purchase price stands at a 41-percent premium over Merus NV's (NASDAQ:MRUS) $68.89 closing price on September 26, and approximately 44 percent over its 30-day volume-weighted average price of $67.42. Genmab said it will
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]Yahoo! Finance
- Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.MarketBeat
- Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated SafetyGlobeNewswire
MRUS
Earnings
- 8/5/25 - Miss
MRUS
Sec Filings
- 11/28/25 - Form 4
- 11/28/25 - Form 4
- 11/14/25 - Form SCHEDULE
- MRUS's page on the SEC website